Hormones in neurodegeneration, neuroprotection, and neurogenesis

INDICE: List of Contributors. Part I Estrogens, Progestins, Allopregnanolone and Neuroprotection. 1 Interactions of Estradiol and Insulin-like Growth Factor-I in Neuroprotection: Implications for Brain Aging and Neurodegeneration (María-Angeles Arévalo, Luis M. Garcia-Segura, and Iñigo Azcoitia). 1.1 Introduction: Hormones, Brain Aging, and Neurodegeneration. 1.2 Estradiol, IGF-I, Brain Aging, and Neuroprotection. 1.3 Molecular Interactions of Estrogen Receptors and IGF-I Receptor in the Brain. 1.4 Regulation of IGF-I Receptor Signaling by Estradiol in the Brain. 1.5 Regulation of Estrogen Receptor TranscriptionalActivity by IGF-I in Neural Cells. 1.6 Implications of the Cross Talk betweenEstrogen Receptors and IGF-I Receptors for Brain Aging, and Neurodegeneration. Acknowledgment. References. 2 StructureNongenomic Neuroprotection Relationship of Estrogens and Estrogen-Derived Compounds (James W. Simpkins, Kun Don Yi,Evelyn Perez, and Douglas Covey). 2.1 Introduction. 2.2 In vitro Assessments of StructureNeuroprotective Activity Relationships. 2.3 In vivo Assessment of StructureNeuroprotective Activity Relationships. 2.4 In vitro Assessment of StructureCell Signaling Relationships. 2.5 Summary. Acknowledgment. References. 3 Progestins and Neuroprotection: Why the Choice of Progestin Matters (Meharvan Singh). 3.1 Introduction. 3.2 The Biology of Progesterone. 3.3 Membrane-Associated Progesterone Receptors. 3.4 Progesterone-Induced Protection. 3.5 Mechanisms Underlying Progesterones Protective Effects. 3.6 Medroxyprogesterone Acetate. Acknowledgments. References. 4 Endogenous and Synthetic Neurosteroids in the Treatment of NiemannPick Type C Disease (Synthia H. Mellon, Wenhui Gong, and Marcus D. Schonemann). 4.1 Introduction. 4.2 NiemannPick Type C Disease as a Model of Disrupted Neurosteroidogenesis. 4.3 Steroidogenesis and Neurosteroidogenesis in NP-C. 4.4 Treatment of NP-C Mice with Allopregnanolone. 4.5 Mechanism of Allopregnanolone Action: GABAA Receptor. 4.6 Mechanism of Allopregnanolone Action: Pregnane-X Receptor. 4.7 Mechanism of Allopregnanolone Action: Reduction of Cellular Oxidative Stress. 4.8 Conclusions Mechanisms of Allopregnanolone Action in Treatment of NP-C and Other Neurodegenerative Diseases. Acknowledgments. References. Part II Glucocorticoids, Dehydroepiandrosterone, Neuroprotection and Neuropathy. 5 Glucocorticoids, Developmental Programming, and the Risk of Affective Dysfunction (Bayanne Olabi and Jonathan Seckl). 5.1 Introduction to Programming. 5.2 Programming. 5.3 Glucocorticoids and Fetal Development. 5.4 Glucocorticoids: the Endocrine Programming Factor. 5.5 Fetal Tissue Glucocorticoid Sensitivity. 5.6 Stress and Glucocorticoids: Key Programmers ofthe Brain. 5.7 CNS Programming Mechanisms. 5.8 Glucocorticoid Programming in Humans. 5.9 Future Perspectives and Therapeutic Opportunities. 5.10 Overview. References. 6 Regul

• ISBN: 978-3-527-32627-3
• Editorial: Wiley-VCH
• Encuadernacion: Cartoné
• Páginas: 404
• Fecha Publicación: 12/01/2011
• Nº Volúmenes: 1
• Idioma: Inglés